Bacteriophages and medical oncology: Targeted gene therapy of cancer

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Bakhshinejad, Babak ^a   Karimi, Marzieh ^a   Sadeghizadeh, Majid ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Bacteriophage; Cancer; Gene therapy; Peptide library; Phage display; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDE; PEPTIDE LIBRARY;

ANTINEOPLASTIC ACTIVITY; BACTERIOPHAGE; BACTERIUM CULTURE; BIOPANNING; CANCER CELL; CANCER GENE THERAPY; CANCER TISSUE; COMBINATORIAL LIBRARY; HUMAN; IMMUNOGENICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT; GENE THERAPY; GENE VECTOR; GENETICS; NEOPLASMS; PROCEDURES;

BACTERIOPHAGES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES;

EID: 84903862004     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0110-9     Document Type: Review

References (85)

1. Dabrowska K, Switala-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol. 2005;98(1):7-13.
2. Viertel TM, Ritter K, Horz HP. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother. 2014;. doi:10.1093/jac/dku173.
3. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228(4705):1315-7. (Pubitemid 15000355)
4. Kulseth MA, Fagerlund A, Myrset AH. Affinity selection using filamentous phage display. Methods Mol Biol. 2014;1088:67-80.
5. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev. 2005;105(11):4056-72. (Pubitemid 41724069)
6. Ebrahimizadeh W, Rajabibazl M. Bacteriophage vehicles for phage display: biology, mechanism, and application. Curr Microbiol. 2014;69(2):109-20.
7. Willats WG. Phage display: practicalities and prospects. Plant Mol Biol. 2002;50(6):837-54. (Pubitemid 36034980)
8. Newton J, Deutscher SL. Phage peptide display. Hand Exp Pharmacol. 2008;185(Pt 2):145-63.
9. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science. 1990;249(4967):386-90.
10. Deutscher SL. Phage display in molecular imaging and diagnosis of cancer. Chem Rev. 2010;110(5):3196-211.
11. Georgieva Y, Konthur Z. Design and screening of M13 phage display cDNA libraries. Molecules. 2011;16(2):1667-81.
12. Pershad K, Kay BK. Generating thermal stable variants of protein domains through phage display. Methods. 2013;60(1):38-45.
13. Hammers CM, Stanley JR. Antibody phage display: technique and applications. J Invest Dermatol. 2014;134(2):e17.
14. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv. 2010;28(6):849-58.
15. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage displayderived peptides as therapeutic alternatives to antibodies. Drug Discov Today. 2004;9(12):525-9. (Pubitemid 38739333)
16. Paschke M. Phage display systems and their applications. Appl Microbiol Biotechnol. 2006;70(1):2-11. (Pubitemid 43234524)
17. Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, Church WB, Dastmalchi S. Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov Today. 2013; 18(23-24):1144-57.
18. Huang JX, Bishop-Hurley SL, Cooper MA. Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother. 2012;56(9):4569-82.
19. Smothers JF, Henikoff S, Carter P. Tech. Sight. Phage display. Affinity selection from biological libraries. Science. 2002;298(5593):621-2. (Pubitemid 35215319)
20. Rangel R, Guzman-Rojas L, le Roux LG, Staquicini FI, Hosoya H, Barbu EM, et al. Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells. Nat Commun. 2012;3:788.
21. Sun N, Funke SA, Willbold D. Mirror image phage display-generating stable therapeutically and diagnostically active peptides with biotechnological means. J Biotechnol. 2012;161(2):121-5.
22. Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol (Camb). 2010;2(7-8):326-37.
23. Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol Pharm. 2014. doi:10.1021/mp400751g.
24. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16(6):510-20.
25. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-68.
26. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165-70. (Pubitemid 47538116)
27. Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Expert Opin Drug Deliv. 2013;10(3):353-67.
28. Gray BP, Brown KC. Combinatorial peptide libraries: mining for cell-binding peptides. Chem Rev. 2014;114(2):1020-81.
29. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-80. (Pubitemid 351752547)
30. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol. 2001;5(3):308-13. (Pubitemid 32718528)
31. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater. 2012;24(28):3747-56.
32. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007;4(5):631-51. (Pubitemid 350004263)
33. Matsuo AL, Juliano MA, Figueiredo CR, Batista WL, Tanaka AS, Travassos LR. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity. Mol Cancer Res. 2011;9(11):1471-8.
34. Jager S, Jahnke A, Wilmes T, Adebahr S, Vogtle FN, Delima-Hahn E, et al. Leukemia-targeting ligands isolated from phagedisplay peptide libraries. Leukemia. 2007;21(3):411-20.
35. Shires K, Shankland I, Mowla S, Njikan S, Jaymacker J, Novitzky N. Serine and proline-rich ligands enriched via phage-display technology show preferential binding to BCR/ABL expressing cells. Hematol Oncol Stem Cell Ther. 2014;7(1):32-40.
36. Schluesener HJ, Xianglin T. Selection of recombinant phages binding to pathological endothelial and tumor cells of rat glioblastoma by in vivo display. J Neurol Sci. 2004;224(1-2):77-82. (Pubitemid 39278265)
37. Bockmann M, Drosten M, Putzer BM. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med. 2005;7(2):179-88. (Pubitemid 40348022)
38. Jayanna PK, Bedi D, Deinnocentes P, Bird RC, Petrenko VA. Landscape phage ligands for PC3 prostate carcinoma cells. Protein Eng Des Sel. 2010;23(6):423-30.
39. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377-80. (Pubitemid 28063372)
40. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5(9):1032-8. (Pubitemid 29439574)
41. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006;125(2):385-98.
42. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18(11):1185-90.
43. Wang W, Li W, Ma N, Steinhoff G. Non-viral gene delivery methods. Curr Pharm Biotechnol. 2013;14(1):46-60.
44. Rogers ML, Rush RA. Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery. J Control Release. 2012;157(2):183-9.
45. Ishiura M, Hirose S, Uchida T, Hamada Y, Suzuki Y, Okada Y. Phage particle-mediated gene transfer to cultured mammalian cells. Mol Cell Biol. 1982;2(6):607-16. (Pubitemid 12058822)
46. Okayama H, Berg P. Bacteriophage lambda vector for transducing a cDNA clone library into mammalian cells. Mol Cell Biol. 1985;5(5):1136-42. (Pubitemid 15110305)
47. Yokoyama-Kobayashi M, Kato S. Recombinant f1 phage particles can transfect monkey COS-7 cells by DEAE dextran method. Biochem Biophys Res Commun. 1993;192(2):935-9. (Pubitemid 23227413)
48. Yokoyama-Kobayashi M, Kato S. Recombinant f1 phage-mediated transfection of mammalian cells using lipopolyamine technique. Anal Biochem. 1994;223(1):130-4. (Pubitemid 24356703)
49. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol. 2006;24(5):212-8.
50. Larocca D, Witte A, Johnson W, Pierce GF, Baird A. Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther. 1998;9(16):2393-9. (Pubitemid 28523988)
51. Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 1999;13(6):727-34. (Pubitemid 29156404)
52. Bach M, Holig P, Schlosser E, Volkel T, Graser A, Muller R, et al. Isolation from phage display libraries of lysine-deficient human epidermal growth factor variants for directional conjugation as targeting ligands. Protein Eng. 2003;16(12):1107-13. (Pubitemid 38281762)
53. Piersanti S, Cherubini G, Martina Y, Salone B, Avitabile D, Grosso F, et al. Mammalian cell transduction and internalization properties of lambda phages displaying the full-length adenoviral penton base or its central domain. J Mol Med (Berl). 2004;82(7):467-76. (Pubitemid 39044286)
54. Lankes HA, Zanghi CN, Santos K, Capella C, Duke CM, Dewhurst S. In vivo gene delivery and expression by bacteriophage lambda vectors. J Appl Microbiol. 2007;102(5):1337-49. (Pubitemid 46633423)
55. Wen WH, Qin WJ, Gao H, Zhao J, Jia LT, Liao QH, et al. An hepatitis B virus surface antigen specific single chain of variable fragment derived from a natural immune antigen binding fragment phage display library is specifically internalized by HepG2.2.15 cells. J Viral Hepat. 2007;14(7):512-9. (Pubitemid 46944475)
56. Delhalle S, Schmit JC, Chevigne A. Phages and HIV-1: from display to interplay. Int J Mol Sci. 2012;13(4):4727-94.
57. Manchester M, Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev. 2006;58(14):1505-22. (Pubitemid 44829893)
58. Bakhshinejad B, Sadeghizadeh M. Bacteriophages as vehicles for gene delivery into mammalian cells: prospects and problems. Expert Opin Drug Deliv. 2014; 1-14. doi:10.1517/17425247.2014.927437.
59. Chanishvili N. Phage therapy-history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res. 2012;83:3-40.
60. Khalaj-Kondori M, Sadeghizadeh M, Behmanesh M, Saggio I, Monaci P. Chemical coupling as a potent strategy for preparation of targeted bacteriophage-derived gene nanocarriers into eukaryotic cells. J Gene Med. 2011;13(11):622-31.
61. Jepson CD, March JB. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine. 2004;22(19):2413-9. (Pubitemid 38757338)
62. Rentero I, Heinis C. Screening of large molecule diversities by phage display. Chimia. 2011;65(11):843-5.
63. Fagerlund A, Myrset AH, Kulseth MA. Construction of a filamentous phage display peptide library. Methods Mol Biol. 2014;1088:19-33.
64. O'Neil KT, Hoess RH, Jackson SA, Ramachandran NS, Mousa SA, DeGrado WF. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins. 1992;14(4):509-15.
65. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010;339(1):269-80.
66. Lyle C, McCormick F. Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J. 2010;7:148.
67. Hutt-Fletcher LM, Chesnokova LS. Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection. Virulence. 2010;1(5):395-8.
68. Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T. Viral and cellular contributions to herpes simplex virus entry into the cell. Curr Opin Virol. 2012;2(1):28-36.
69. Hauck CR, Borisova M, Muenzner P. Exploitation of integrin function by pathogenic microbes. Curr Opin Cell Biol. 2012;24(5):637-44.
70. Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007;8(5):215.
71. Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, et al. Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem. 1994;269(17):12468-74. (Pubitemid 24202027)
72. Dunn IS. Mammalian cell binding and transfection mediated by surface-modified bacteriophage lambda. Biochimie. 1996;78(10):856-61. (Pubitemid 27060984)
73. Bedi D, Gillespie JW, Petrenko VA Jr, Ebner A, Leitner M, Hinterdorfer P, et al. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm. 2013;10(2):551-9.
74. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110-6.
75. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 2001;3(6):964-75. (Pubitemid 32611306)
76. Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol. 2000;74(11):5320-8. (Pubitemid 30313874)
77. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A. 2002; 99(20):12617-21.
78. Hamzeh-Mivehroud M, Mahmoudpour A, Rezazadeh H, Dastmalchi S. Non-specific translocation of peptide-displaying bacteriophage particles across the gastrointestinal barrier. Eur J Pharm Biopharm. 2008;70(2):577-81.
79. Costantini TW, Eliceiri BP, Putnam JG, Bansal V, Baird A, Coimbra R. Intravenous phage display identifies peptide sequences that target the burn-injured intestine. Peptides. 2012;38(1):94-9.
80. Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol. 2006;24(4):455-60.
81. Li J, Zhang Q, Pang Z, Wang Y, Liu Q, Guo L, et al. Identification of peptide sequences that target to the brain using in vivo phage display. Amino Acids. 2012;42(6):2373-81.
82. Wan XM, Chen YP, Xu WR, Yang WJ, Wen LP. Identification of nose-to-brain homing peptide through phage display. Peptides. 2009;30(2):343-50.
83. Kassner PD, Burg MA, Baird A, Larocca D. Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells. Biochem Biophys Res Commun. 1999;264(3):921-8.
84. Larocca D, Burg MA, Jensen-Pergakes K, Ravey EP, Gonzalez AM, Baird A. Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol. 2002;3(1):45-57. (Pubitemid 34233033)
85. Filee J, Tetart F, Suttle CA, Krisch HM. Marine T4-type bacteriophages, a ubiquitous component of the dark matter of the biosphere. Proc Natl Acad Sci U S A. 2005;102(35):12471-6. (Pubitemid 41266383)